Many politicians, including the President, threw their weight behind the Volcker Rule even though, as Taylor points out, it was more like a hatchet than a scalpel and is now poised to present a number of unintended consequences.

InsideCounsel recently spoke with Goodwin Procter’s Elaine Blais, one of the authors of “Biosimilars: A guide to Regulatory and Intellectual Property Issues” about matters of concern for attorneys in this space.